| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 通关藤苷F; Tenacissoside F | CFN97496 | 928151-78-4 | C35H56O12 = 668.8 | 5mg | QQ客服：3257982914 |
| 酸浆苦素L; Physalin L | CFN90166 | 113146-74-0 | C28H32O10 = 528.55 | 5mg | QQ客服：215959384 |
| 短葶山麦冬皂苷C; Liriope muscari baily saponins C | CFN90194 | 87480-46-4 | C44H70O14 = 855.02 | 20mg | QQ客服：2159513211 |
| 日本蟾蜍毒苷元; Gamabufotalin | CFN90212 | 465-11-2 | C24H34O5 = 402.52 | 20mg | QQ客服：2056216494 |
| 远华蟾蜍精; Telocinobufagin | CFN90213 | 472-26-4 | C24H34O5 = 402.52 | 20mg | QQ客服：215959384 |
| 土克甾酮; Turkesterone | CFN90217 | 41451-87-0 | C27H44O8 = 496.64 | 5mg | QQ客服：1413575084 |
| 苦绳甙Ga1; Dregeoside Ga1 | CFN97588 | 98665-66-8 | C49H80O17 = 941.17 | 5mg | QQ客服：1457312923 |
| Adynerigenin beta-neritrioside; Adynerigenin beta-neritrioside | CFN97597 | 88721-09-9 | C42H64O17 = 840.96 | 5mg | QQ客服：1413575084 |
| Marsdenoside F; Marsdenoside F | CFN97605 | 858360-61-9 | C39H60O14 = 752.90 | 5mg | QQ客服：1413575084 |
| 11,12-二-O-乙酰基通光藤苷元B; 11,12-Di-O-acetyltenacigenin B | CFN97606 | 857897-01-9 | C25H36O7 = 448.56 | 5mg | QQ客服：2056216494 |
| 重楼皂苷D; Polyphyllin D | CFN90255 | 50773-41-6 | C44H70O16 = 855.02 | 20mg | QQ客服：3257982914 |
| 乌沙苷元洋地黄苷; Uzarigenin digitaloside | CFN97718 | 61217-80-9 | C30H46O8 = 534.69 | 5mg | QQ客服：215959384 |
| 去氢欧夹竹桃甙元洋地黄苷; Dehydroadynerigenin digitaloside | CFN97729 | 52628-62-3 | C30H42O8 = 530.66 | 5mg | QQ客服：215959384 |
| 欧夹竹桃苷乙; Adynerin | CFN97751 | 35109-93-4 | C30H44O7 = 516.68 | 5mg | QQ客服：1413575084 |
| 7 beta-甲氧基豆甾-5-烯-3beta-醇; Schleicheol 1 | CFN97772 | 256445-66-6 | C30H52O2 = 444.74 | 5mg | QQ客服：2159513211 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)